Neuberger Berman Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Neuberger Berman Group’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-236,158	Closed	-$13M	–	1748
2020 Q3	$13M	Buy	236,158 +2,000	+0.9%	+$127K	0.02%	683
2020 Q2	$14.8M	Buy	234,158 +189,158	+420%	+$13M	0.02%	633
2020 Q1	$2.3M	Buy	45,000 +2,499	+6%	+$167K	﹤0.01%	915
2019 Q4	$3.38M	Sell	42,501 -27,499	-39%	-$1.63M	﹤0.01%	923
2019 Q3	$3.4M	Sell	70,000 -16,800	-19%	-$876K	﹤0.01%	910
2019 Q2	$4.57M	Buy	86,800 +35,300	+69%	+$2.03M	0.01%	871
2019 Q1	$2.73M	Buy	51,500 +16,000	+45%	+$786K	﹤0.01%	929
2018 Q4	$1.46M	Buy	35,500 +28,000	+373%	+$1.05M	﹤0.01%	1041
2018 Q3	$285K	Hold	7,500	–	–	﹤0.01%	1449
2018 Q2	$339K	Sell	7,500 -7,800	-51%	-$355K	﹤0.01%	1475
2018 Q1	$739K	Sell	15,300 -7,200	-32%	-$402K	﹤0.01%	1266
2017 Q4	$885K	Buy	+22,500	New	+$840K	﹤0.01%	1255

Other funds holding GBT

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Neuberger Berman Group's GBT Position: Q4 2020 in Review

Neuberger Berman Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 236,158 shares — an estimated $13M sold.

Neuberger Berman Group first reported a position in GBT in Q4 2017 and held it in 12 quarters. The position peaked at $14.8M in Q2 2020. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

Neuberger Berman Group reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Neuberger Berman Group sold 236,158 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $13M.
Neuberger Berman Group first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 12 quarters.
Neuberger Berman Group's Global Blood Therapeutics, Inc. position peaked at $14.8M in Q2 2020.
228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Neuberger Berman Group's 13F filing for Q4 2020, filed 10 Feb 2021.